Schwab Andrew J.'s Form 4 filing
Latigo Biotherapeutics, Inc. (LTGO) · filed Aug 12, 2026
- Accession no.
- 0001231919-26-000869
- Filed
- Aug 12, 2026, 4:13 PM ET
- Trade date
- Aug 10, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 4 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schwab Andrew J.CIK 0001598549 | 10% Owner |
| Parmar KushCIK 0001664281 | 10% Owner |
| 5AM Ventures VI, L.P.CIK 0001753037 | 10% Owner |
| 5AM Partners VI, LLCCIK 0001829051 | 10% Owner |
| 5AM Opportunities II, L.P.CIK 0001844401 | 10% Owner |
| 5AM Opportunities II (GP), LLCCIK 0001873515 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | CConversionDisposed | −3,152,305 | $0.00 | $0 | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −1,823,238 | $0.00 | $0 | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −866,018 | $0.00 | $0 | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −1,484,401 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date.
Referenced by the price of 2 transactions in Table I.